Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR plus NSCLC

被引：2

作者：

Chen, Lanyi Nora ^{[1
]}

Lee, Alexandria T. M. ^{[2
]}

Nagasaka, Misako ^{[1
,2
,3
]}

Ou, Sai-Hong Ignatius ^{[2
,3
,4
]}

机构：

[1] Columbia Univ, Vagelos Coll Phys & Surg, Irving Med Ctr, Dept Med,Div Hematol Oncol, New York, NY USA

[2] Univ Calif Irvine, Sch Med, Orange, CA USA

[3] Chao Family Comprehens Canc Ctr, Orange, CA USA

[4] Univ Calif Irvine, Sch Med, Dept Med, Div Hematol & Oncol, 200 South Manchester Ave, Suite 400, Orange, CA 92868 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 03期

关键词：

CELL LUNG-CANCER;

D O I：

10.1016/j.jtho.2023.12.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：380 / 384

页数：5

共 50 条

[21] Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Cheng, Ying
He, Yong
Li, Wei
Zhang, He-long
Zhou, Qing
Wang, Buhai
Liu, Chunling
Walding, Andrew
Saggese, Matilde
Huang, Xiangning
Fan, Minhao
Wang, Jia
Ramalingam, Suresh S.
TARGETED ONCOLOGY, 2021, 16 (02) : 165 - 176
[22] Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Ying Cheng
Yong He
Wei Li
He-long Zhang
Qing Zhou
Buhai Wang
Chunling Liu
Andrew Walding
Matilde Saggese
Xiangning Huang
Minhao Fan
Jia Wang
Suresh S. Ramalingam
Targeted Oncology, 2021, 16 : 165 - 176
[23] Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC
Wehler, T.
Wehler, B.
Atmaca-Dirik, H.
Schulz, C.
Grohe, C.
Topsch, J.
Ehrlich, A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S800 - S801
[24] Tepotinib plus Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
Dooms, C.
Nadal, E.
Raskin, J.
Demedts, I.
Mazieres, J.
Wislez, M.
Abdul, S.
Mun, T. L.
Wang, C.
Viteri, S.
Le, X.
How, S. H.
Tan, D.
Takeda, M.
Veillon, R.
Karachaliou, N.
Ellers-Lenz, B.
Smit, E.
Wu, Y.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1099 - S1100
[25] Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC
Lu, S.
Yu, Y.
Yu, X.
Hu, Y.
Ma, Z.
Li, X.
Zhuang, W.
Liu, Y.
Li, W.
Cui, J.
Wang, D.
Liao, W.
Wang, M.
Zhou, J.
Wang, Z.
Sun, Y.
Gao, J.
Bao, Y.
Liang, L.
Wang, J.
ANNALS OF ONCOLOGY, 2020, 31 : S816 - S817
[26] First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Ji, W.
Jiang, D.
Zhang, J.
Zhang, H.
Wang, Q.
Cang, S.
Li, X.
Tan, J.
Xiang, Y.
Li, X.
Liu, A.
Lu, S.
ANNALS OF ONCOLOGY, 2023, 34 : S1693 - S1693
[27] EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
Stock-Martineau, Sophie
Shepherd, Frances A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1793 - 1797
[28] Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset
Cho, Byoung Chul
Chewaskulyong, Busayamas
Lee, Ki Hyeong
Dechaphunkul, Arunee
Sriuranpong, Virote
Imamura, Fumio
Nogami, Naoyuki
Kurata, Takayasu
Okamoto, Isamu
Zhou, Caicun
Cheng, Ying
Cho, Eun Kyung
Voon, Pei Jye
Lee, Jong-Seok
Mann, Helen
Saggese, Matilde
Reungwetwattana, Thanyanan
Ramalingam, Suresh S.
Ohe, Yuichiro
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (01) : 99 - 106
[29] Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC
Zhou, C.
Cheng, Y.
He, Y.
Li, W.
Zhang, H.
Zhou, Q.
Wang, B.
Liu, C.
Ramalingam, S.
Walding, A.
Saggese, M.
Wang, J.
Fan, M.
Wu, Y.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S507 - S508
[30] OSIMERTINIB MAY BE AN EFFECTIVE FIRST-LINE THERAPY IN EGFR-MUTANT NSCLC
不详
CANCER DISCOVERY, 2017, 7 (10) : 1061 - 1061

← 1 2 3 4 5 →